<SEC-DOCUMENT>0001396814-19-000002.txt : 20190103
<SEC-HEADER>0001396814-19-000002.hdr.sgml : 20190103
<ACCEPTANCE-DATETIME>20190103073520
ACCESSION NUMBER:		0001396814-19-000002
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190103
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190103
DATE AS OF CHANGE:		20190103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pacira Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001396814
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510619477
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35060
		FILM NUMBER:		19503633

	BUSINESS ADDRESS:	
		STREET 1:		5 SYLVAN WAY
		STREET 2:		SUITE 300
		CITY:			PARSIPPANY
		STATE:			NJ
		ZIP:			07054
		BUSINESS PHONE:		973-254-3560

	MAIL ADDRESS:	
		STREET 1:		5 SYLVAN WAY
		STREET 2:		SUITE 300
		CITY:			PARSIPPANY
		STATE:			NJ
		ZIP:			07054

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIRA INC
		DATE OF NAME CHANGE:	20080318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Blue Acquisition Corp
		DATE OF NAME CHANGE:	20070418
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a2018revenue8-k.htm
<DESCRIPTION>8-K 2018 EXPAREL NET SALES PRESS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sd71751c7497b47268eb05c4fb115d8f5"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:188%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;font-weight:bold;">&#160;</font></div><div style="line-height:113%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:194%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:133%;padding-top:14px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:117%;text-align:center;padding-left:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:117%;text-align:center;padding-left:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-top:14px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported): January 3, 2019</font></div><div style="line-height:192%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">PACIRA PHARMACEUTICALS, INC.</font></div><div style="line-height:113%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:113%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.03125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:28%;"></td><td style="width:7%;"></td><td style="width:29%;"></td><td style="width:7%;"></td><td style="width:29%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-35060</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">51-0619477</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:117%;text-align:center;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:108%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5 Sylvan Way, Suite 300</font></div><div style="line-height:108%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Parsippany, New Jersey 07054</font></div><div style="line-height:110%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address and Zip Code of Principal Executive Offices)</font></div><div style="line-height:110%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:111%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(973) 254-3560</font></div><div style="line-height:114%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s Telephone Number,&#160;Including Area Code)</font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company&#160; </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</font><font style="font-family:Wingdings;font-size:9.5pt;">o</font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:2px;-sec-extract:summary;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02. Results of Operations and Financial Condition.</font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:112%;text-align:left;padding-left:1px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 3, 2019, Pacira Pharmaceuticals, Inc. issued a press release announcing its preliminary unaudited EXPAREL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;net product sales for the fourth quarter and full-year ended December 31, 2018. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</font></div><div style="line-height:112%;text-align:left;padding-left:1px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:117%;text-align:left;padding-left:1px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</font></div><div style="line-height:117%;text-align:left;padding-left:1px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01. Financial Statements and Exhibits.</font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) The following exhibits are included in this report:</font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</font></div><div style="line-height:100%;text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">No.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description &#160;&#160;&#160;&#160;</font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1&#160;&#160;&#160;&#160;         </font><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit991.htm"><font style="font-family:inherit;font-size:10pt;">Press Release dated January 3, 2019</font></a></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:113%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:113%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:112%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:113%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:113%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:5%;"></td><td style="width:20%;"></td><td style="width:37%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PACIRA PHARMACEUTICALS,&#160;INC.<br>(REGISTRANT)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 3, 2019</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">/s/ KRISTEN WILLIAMS</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kristen Williams</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Administrative Officer and Secretary</font></div></td></tr></table></div></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:100%;text-align:center;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:100%;text-align:center;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;padding-left:1px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:2%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit991.htm"><font style="font-family:inherit;font-size:10pt;">Press Release dated January 3, 2019</font></a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8cd58614828d4a9d8b20a79174e06e5b"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:left;"><img src="paciralogoa08.jpg" alt="paciralogoa08.jpg" style="height:58px;width:150px;"></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NEWS RELEASE</font></div><div style="line-height:113%;text-align:center;padding-left:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pacira Reports Preliminary 2018 Net EXPAREL</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;Sales of $331 Million</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">-- EXPAREL sales exceed upper end of guidance with expanding support from</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">physicians, payers, and patients --</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PARSIPPANY, N.J., January 3, 2019 </font><font style="font-family:inherit;font-size:12pt;">&#8212; Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported preliminary unaudited EXPAREL</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(bupivacaine liposome injectable suspension) net product sales of $94 million for the fourth quarter of 2018 and $331 million for the full-year, as compared to $79 million and $283 million reported for the fourth quarter and full-year 2017, respectively. The company previously guided to full-year EXPAREL net product sales of $325 to $330 million.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;We are very pleased with our 2018 results, with fourth quarter EXPAREL sales exceeding our expectations and marking the highest quarterly revenues ever reported by Pacira,&#8221; said Dave Stack, chairman and chief executive officer of Pacira. &#8220;With an expanding number of payers, providers and patients recognizing the value of EXPAREL as a critical component within opioid-sparing pain management strategies, we are entering 2019 with strong momentum. Our robust partnership network also remains a core driver as we continue to focus on maximizing the value of EXPAREL, including its role in transitioning certain inpatient procedures to the ambulatory setting. We are particularly excited by new reimbursement codes, which went into effect on January 1, 2019, that we believe will meaningfully expand patient access through a product-specific C-code for ambulatory surgery centers and a procedure-based D-code for the oral surgery setting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Looking ahead, we have put in place a number of growth initiatives that include building a pipeline of innovative non-opioid pain management and regenerative health solutions. Our goal is that these, coupled with our unique experience and position in the marketplace as a leader in non-opioid postsurgical pain management, will make a key contribution in confronting the current U.S. pain and opioid crises.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The financial information included in this press release is preliminary, unaudited and subject to adjustment. It does not present all information necessary for an understanding of the company&#8217;s fourth quarter and full-year financial results for 2018. Pacira expects to report its complete financial results for 2018, along with financial guidance for 2019, during the company&#8217;s fourth quarter earnings call, which will take place in the first quarter of 2019.</font></div><div style="line-height:113%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Pacira</font></div><div style="line-height:120%;padding-top:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company&#8217;s flagship product, EXPAREL</font><font style="font-family:inherit;font-size:12pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(bupivacaine liposome injectable suspension), is redefining pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. EXPAREL utilizes DepoFoam</font><font style="font-family:inherit;font-size:12pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.pacira.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About EXPAREL&#174;</font></div><div style="line-height:120%;padding-top:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. The product combines bupivacaine with DepoFoam&#174;, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.EXPAREL.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:115%;text-align:left;padding-left:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Important Safety Information</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EXPAREL is contraindicated in obstetrical paracervical block anesthesia. Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation. If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20&#160;minutes after injecting lidocaine. EXPAREL is not recommended to be used in the following patient population: patients &lt;18&#160;years old and/or pregnant patients. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Warnings and Precautions Specific to EXPAREL</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Avoid additional use of local anesthetics within 96&#160;hours following administration of EXPAREL. EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">other than interscalene brachial plexus nerve block</font><font style="font-family:inherit;font-size:12pt;">, or intravascular or&#160;intra-articular use. The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5&#160;days, as seen in clinical trials.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Warnings and Precautions for Bupivacaine-Containing Products</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Central Nervous System (CNS) Reactions: </font><font style="font-family:inherit;font-size:12pt;">There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cardiovascular System Reactions: </font><font style="font-family:inherit;font-size:12pt;">Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Allergic Reactions:</font><font style="font-family:inherit;font-size:12pt;">&#32;Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Chondrolysis:</font><font style="font-family:inherit;font-size:12pt;">&#32;There have been reports of chondrolysis (mostly in the shoulder joint) following&#160;intra-articular infusion of local anesthetics, which is an unapproved use.</font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward Looking Statements</font></div><div style="line-height:113%;text-align:left;padding-left:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">Any statements in this press release about the company&#8217;s future expectations, plans, outlook and prospects, and other statements containing the words &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could&#8221; and similar expressions, constitute forward-looking statements </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of the company&#8217;s sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and the company&#8217;s ability to serve those markets; the company&#8217;s plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications; the outcome of the U.S. Department of Justice inquiry; the company&#8217;s plans to evaluate, develop and pursue additional DepoFoam-based product candidates; clinical trials in support of an existing or potential DepoFoam-based product; the company&#8217;s commercialization and marketing capabilities; the company&#8217;s and Patheon UK Limited&#8217;s ability to successfully and timely construct dedicated EXPAREL manufacturing suites; and other factors discussed in the &#8220;Risk Factors&#8221; of the company&#8217;s most recent Annual Report on Form 10-K and in other filings that the company periodically makes with the SEC. In addition, the forward-looking statements included in this press release represent the company&#8217;s views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such the company anticipates that subsequent events and developments will cause its views to change. However, while the company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company&#8217;s views as of any date subsequent to the date of this press release.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">###</font></div><div style="line-height:113%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Investor Contact:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Susan Mesco, (973) 451-4030</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">susan.mesco@pacira.com</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Media Contact:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Coyne Public Relations</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Alyssa Schneider, (973) 588-2270</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">aschneider@coynepr.com</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>paciralogoa08.jpg
<TEXT>
begin 644 paciralogoa08.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0#017AI9@  34T *@    @ " $Q  (
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M# P,# P,# S_P  1" '!!' # 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M16Z-_/VKLJDH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV$[6Z_*V",'BNIKYZ<)0ERS5FNC.1IIV84445(@HHHH **** "BBB@ HHHH
M**** "L?X@>/]&^%7@?5O$OB+4+?2=#T*TDOK^\F)\NWAC4L['&2< = "2>
M"2!6Q7YD_P#!RU^U]_PK?]GW0?A'I-TJ:MX^G%_JR*?FCTVW<%5/IYMP%P1U
M%O(#P:]+)\NECL93PL?M/5]ENW]QMAZ+JU%!=3Z^^!O_  4V^!/[2GQ'L_"/
M@CXB:7KWB34$DDMK&.VN8GF6-#(^TR1JIPBLV,YP#Z5[Q7\G/[._QKU3]G#X
MZ>$_'FC?\A+PIJD&HQ(6VK.$<%XF/]UUW(?9C7]5'PN^)&E?&'X;:#XLT.X6
MZT;Q)I\&I64H_CBE0.N?0X;D=CD5[G%G#<<KG!T6Y0DGJ[737HETV^9U8[!J
M@UR[,WJ***^1//"BBB@ HHHH **** "BBO//CE^T?H?P3L6CF87VLR+NAL(G
MPWLSGG8ON>3V!YP =EXJ\6Z;X(T2;4M6O(;&S@&6DD;'/8 =2Q[ 9)KY:^-_
M[8FH^.3-IOAWSM*TELHT^=MS=#ZC[BGT')[GDBO+_B?\7]<^+^NF\UBZ+JF?
M(MD^6&W![*O]3DGN:P8>E:<ME<ELLQ'-6X>E4X>E7K9&D9552S-P !R352))
M8?O5?TRQFU.ZCM[>&2XGF(5(XU+,Y] !R:],^$_[)&N>,O+O-8+:)IS88*ZY
MN91[)_#GU;GV-?1GP_\ A3H7PSLO*TFQCBD88DN'^>:7ZL><>PP/:I<BN4\/
M^&O[(6J:P([GQ!-_9=N<'[/'A[AA[_PK^I]A7NW@KX<:+\/K/R=*L8K<D8>4
MC=+)_O,>3].GM6Y14.390445YW^T#^UI\-?V5M"&H?$+QIH/A6%UWQ17EP/M
M-R,X_=0+F67H?N*W0U=.E.I)0IIMOHE=CC%MV1Z)17Y>_M#_ /!SU\/_  E)
M/9_#7P1KWC"X0E%O]5E72[(^CH@$DKK[,L9KXK^-G_!PK^TA\6O.ATO7-!\!
MV4N5,6@:6GF%>W[VX,L@;_:1EY]!Q7U6"X(S7$*\HJ"_O.WX*[^]'?3RRO/=
M6]3^A:N+\<?M)?#KX9-(/$GC[P7X>,)(<:GKEM:;,=<^8XQ7\O/Q0_:K^)WQ
MK>3_ (2[XA>-/$JR J8]1UFXN(@IZJ$9RH4^@ %<#7TE#PWZUJ_R4?U;_0[(
MY-_-+\#^GK7_ /@JC^SEX;G\NX^,_P /Y&W%<VNJI=KD>\6X8]^A[5S5Q_P6
MH_9>M;B2-OB[HA:-BI*65XZDCCAA"01[@X-?S545Z$?#G _:JS_#_)FW]CTN
MLG^!_2I#_P %J?V79YEC7XNZ*&<A06L;U5Y]28<#ZGBNBT;_ (*M?LX:[,T<
M'QF\!QLI S<:BMLO/O)M'^%?S$T42\.<#]FI/\/\D']CTN[_  /ZN?!W[5_P
MM^(CJOA_XE> -<9SA1I_B&TNBW;C9(>]=^K!U#*<J>01WK^0>NN^''[0'CSX
M.RJ_A'QKXL\+M'G:=)U>XLL9.3_JW7J>OK7!6\-UO1K_ 'Q_5/\ 0QEDW\LO
MP/ZRJ*_G.^#7_!>?]ICX/R1))XVM_%]C#C_1?$6G170;ZS($G/\ W\K[#^ W
M_!TCIMUY-M\3OAC>6;<"34/#-ZLZM]+:?:5 _P"NS'GIQS\]C.!<THZP2FO[
MK_1V_"YR5,KKQVU]#];J*^=_V<O^"K?P!_:DEM[7PQ\1M%AU:X "Z7JY.F7A
M<X^14G"B5N?^61<=>>*^B*^5Q&%K4)<E>#B^S37YG!.G*#M)6"BBBN<D****
M "BBOQD_;)_X+O?'/]DS]M?XC^"]-3P3X@\/^'=;EMK*'5=)</%!]Y4WPRQD
ME0P&YLD[03WSZV4Y+B,RJ2IX:UXJ^KMI>QT8?#SK-Q@?LW17XM^'O^#IKQI;
M6VW5OA+X7O9L##6FK3VJYYS\K)(?3OQ@]<\3ZK_P=/>*YK7;8_"#P];SY^_/
MKDTRX_W1$A].]>O_ *CYQ>WLU_X%'_,Z/[,Q';\4?L[17X-^(/\ @Y$_:$^(
MVLVVG:/8_#WPJ+Z9+>.6UTF:XDC+D+N)GF=3@G/W!T'![_O)7F9QD.*RU0^M
M6]^]K.^UM_O,,1A9T;<_4****\4Y@HHHH ***_&G_@I3_P %H_CY^R'^WE\0
M/ ?A_4/#O_"/Z#=6C6-M>Z3%,T<4MG;SX+J0Q#>:3R<C.,C%>MD^35\RJNCA
M[72OJ[:72[/N=&'P\ZTN6!^RU%?@YHW_  <W?M :<NVX\._"O4 7R6ETJ]1@
M/0;+M1^)!KK-*_X.D/B=#YGV[X:^!+C.-GD3W<.WKG.YWSV],>_;W)<!YLMH
MI_\ ;R_6QTO*\0NB^\_;>BOQFLO^#J#Q-':HMS\'="FF'WGCU^6-3]%,+$?F
M:E_XBH_$'_1&='_\*.3_ .1ZQ_U)SC_GU_Y-'_,G^S,1_+^*/V4HK\9;_P#X
M.H/$\EHRVOP=T&&?C:\NO2R(.><J(5)XSW']*Y?Q%_P=%?%RY#?V3\/?AS8]
M-OVL7MUCUSMFCSG\,>]5'@;-WO32_P"WE^C8UE>([?BC]PJ*_ 36_P#@Y*_:
M.U5LVZ^ --^8MBVT1VX/\/[R9^!^?N:YZ_\ ^#A;]J"\NVDC\6:#:HV,11>'
MK0HO&.-R,W/7DGK75'P_S1[N"^;_ ,C3^R:_E]Y_0Y17\\=A_P '"W[4%G=K
M))XLT&Z1<YBE\/6@1N,<[45N.O!'2NL\,?\ !RU^T-H3I]LT_P"'&M*N0WVK
M1YXRV3ZPW"8(Z#C'J#1/P_S2.S@_1O\ 5(3RFOY?>?OA17XV_#S_ (.GM=M7
M5/%GPATF^5N&FTG6Y+0K[B.2*7/TWCKU]?I?X)?\''?[/?Q.GM[7Q"WBOP!=
M285WU73OM%H&/826S2-MZ#<Z(!WP.:\O%<)9M05Y46U_=M+\$V_P,)Y?7CO'
M[M3[WNK6*^MWAFCCFAD&&1U#*P]"#Q7E?Q$_92TGQ&)+C19/[(NFY\O&ZW<_
M3JOX<>U==\)?CEX-^/7AL:QX)\5:!XKTWC=<:5?1W21DYPK["=C<'Y6P1@\<
M5U5?/2C*$N62LUT9QRC;1GQ7X_\ ACKGP[NS'JEC)#&QPDZ_-#)]&''X'!]J
MY>3H:^]K_3[?5;.2WNH8;BWF&UXY4#(X]"#P:\9^*/['MCK(DN_#<RZ?<'YC
M:2DM Y_V3U3]1]*:EI8GE/F2?J:A%Q):S+)$[1R1D,KJ=K*1T(-;?C7P5JO@
M35&L]6L9[*?G:'7Y9 #U5NC#W!-8,W2J>Q)[M\%?VS9](:/3?%S275KPL>HH
MNZ6/M^\ ^\/]H?-[-7TEI.KVNO:=#>65Q#=6MPNZ.6)PZ./8BOSLGZFNL^$O
MQWUWX-:GYFGS?:+"1LSV,S$PR^I']UO]H?CD<5+CV*4C[OHKC?A#\<]"^,VE
M^;ILWE7L2YN+*4@30^^/XE_VAQ]#Q795F4%%%% !1110 4444 %%%% !1110
M V2188V9F55499B< #U-?.?@[_@KE^SCX_\ 'FF>&='^*FB7VM:Q?1Z;96Z6
MUT!<7$CB-$5S$$^9B #NP<CFN+_X+A_M?_\ #)W["6OQZ?>+;^*/'N?#FE;6
M_>1K*I^TS#N-D&\!A]UY(O45_.?I^H3Z3J$%U:S26]U:R++#+&Q5XG4Y5@1R
M"" 0:^[X8X1AF6&GB*\G%7M&UM;;MW3TOIIV9ZF!R]5H.<G;L?UY45XW_P $
M_OVHH?VR/V0?!'C]9(6U#5K!8M5CC  AOXOW5RNT?='F*S*/[K*>]>R5\5B*
M,Z-65&HK.+:?JM#S91<9.+W04445B2%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5_-G_P6]TV32?\ @J9\6HI55&:\LI@
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M7#?WGD<EF/N36?5G1]'O/$6K6NGZ?:W-]?7LJP6]M;Q-+-/(QPJ(J@EF)(
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M'NAEEV[LJ-0@+9'I@$GVK^IBOR7Q(E^_HKR?YH\#./CBO(****_-3Q@HHHH
M**** "OR;_X+J?\ !';3]6\-ZQ\;OA7I$=GJFGK)?>+=%M$Q'?1#YI+^%.BR
M(,M*J@!UR_#AO,_62FR1K-&RLJLK##*1D$>AKU,IS:OE^(6(H/U71KL_ZTW-
ML/B)49\\3^0FBOJK_@LA^Q7;_L2?MKZWH^CVJVOA#Q-&->T&-%PEM!*S![<>
MT4JR(HR3L\LGDU\JU_0^#Q5/$T(8BE\,DFCZ^G44XJ<=F%?KY_P;4_MW7-U<
M:M\!?$5XTL,<4NL>%6D;_5 '==6@]CN\Y1VQ-Z@5^0=>E?L=_'6X_9F_:F\
M^/+>:2$>&=:M[JY*$YDMMX6XCXYP\+2(?9C7!GV61Q^!J8=K6UX^4EM_EZ,R
MQ5%5:3A]WJ?U744V&9+F%9(V62.0!E93E6!Z$&G5_.9\>%,N+>.[@>*6-)(Y
M 5='7<K ]01WI]% 'SW\=/V([77O.U/P?Y=C>'YGTYSMMY3_ -,S_ ?8_+_N
MBOECQ-X?OO"VKSV.I6L]E>6[;9(9D*LOX>A['H:_2NN1^+7P2T#XS:-]FUBU
M'VB-2(+R+"W%N?\ 9;N/]DY!],\U49=R7$_.V3H:[SX#?M*ZU\!]8VPLU]HL
M[YN=/D?"GU=#_ _OT/<'C%KXZ_LS^(/@E=--/'_:&C2-B+4(4.SV$@_@;Z\'
ML3SCRZ?J:TT9)^E/PQ^*FB_%[PQ'JNB72W$+?+)&>);=^Z.O\+?H1R"1@UT5
M?FA\,OBSK?P=\3QZMH=T8)@ LL3?-#<IG[CKW'ZCJ"#S7W9^S_\ M'Z)\?-"
M\RS9;/5K=<W>GR/F2+MN4_QH?[PZ9 .#6<HV+3/0Z***D84444 %?B?_ ,',
MO[7_ /PF_P 8_#?P;TF\5].\&Q#6-:2-N&OYT_<QM[QV[;A_U]'TX_83X\?&
M71_V>?@QXH\<:])Y>D>%=-FU*XPP5I1&I(C7/!=VPBCNS =Z_E;^-7Q<UCX]
M_%SQ)XU\03>?K7BC49]2NV&=JO*Y;:H[(N0JCLJ@=J_0/#_*_;8N6,FO=IZ+
M_$_\E?[T>ME-#FJ>T>R_,Y>BBBOV0^B"OWA_X-O?VM/^%Q?LD:A\.=2N?,UK
MX97?EVP8_-)IMP6DA.>IV2B9/]E1$.XK\'J^IO\ @C;^UI_PR'^WGX2U6\N?
ML_ASQ,__  CFMDGY5M[EE"2'T$<ZPR$]=J,.]?.<597]>RZ=.*]Z/O1]5T^:
MNCCQU'VM%I;K5']*5%%%?S\?)A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?AA_P '0>D^3^VSX'OO,S]H\$00;-OW?+O[
MULY]_,Z8XV^_'[GU^)7_  =(Z6D/[2OPSO0S>9<>&98"O\("73L#^/F'\A7V
M/ LK9M%=U+\CT,K_ -X7S/R\HHHK]S/J#[N_X-S?^4EFE_\ 8OZE_P"@+7]!
M5?SZ_P#!N;_RDLTO_L7]2_\ 0%K^@JOQ/Q _Y&B_P+\V?-9M_'^2"BBBOASS
M HHHH **** "BBB@#\E_^#IOX8PW/@GX2^,XXU6>SOK[19Y!UD66..:('_=,
M,I'^^?:OQOK]ZO\ @YETN/4/^">^BS.SAK'QK8SQA3P6-I>Q\^V'/3'.*_!6
MOW3@6LYY3!/[+DOQO^I]1E<KX=>5PHHHK[ ] _IX_P""5GC^3XE_\$Z/@[JD
MSO)*OAFVL'=SEG:U!MB2<#)/DYSW]3U/T!7R%_P0:8M_P2A^%.23_P A8<_]
MAB^KZ]K^;,XIJ&/KP6RG)?=)GQN(5JLDN[_,****\XQ"BBB@ HHHH *_#C_@
MY4_:_'Q/_:(T/X3Z3=>9I/P]A^UZH(VRLNI7" A3V)B@* =PTTH/(K]C?VFO
MCSI/[+_P \7?$#6V7^S_  KILMZT98*;B0#$4*D\;I)"D:^[BOY7OB?\1]6^
M,/Q'U[Q7KUP;O6O$E_/J5]-V>:5R[X'898X'88%?H?A]E?M<3+&S6D-%_B?^
M2_-'KY30YINH^GYF%7Z*_M]?\$CF_9H_X)>_"CX@V^FB+Q?H^)/'!"XDVZ@R
MO '_ .O9REN<9R9<]!QXS_P1>_9%/[7?[>'A>ROK9IO#/A%O^$CUHE<QM%;L
MIBA/8^9.8D(SDH9",XK^A_XY?!_1_P!H'X.^)O!.O0B;1_%&G3:=<C&619$*
MAU]&4X93V90>U?1<5<32P..H4:;TB^:?FGI;[KO[F=>.QCI58Q735G\F-%=3
M\;OA#K'P!^+_ (E\$Z_#Y.L>%]1FTVZ ^ZSQN5WJ>ZL &4]PP-<M7WL)QG%3
MB[IZH]9--71L?#SQ[JGPK\?:+XFT.Z:SUGP]?0ZE8SKUAGA<2(WX,HXK^J;]
MF3X\:7^T]^S]X1^(&C[5L/%6F17PC#;C;2$8EA)_O1R!T/NAK^4&OV:_X-B_
MVM/[>\">,/@SJESNNM!D/B+0U8\FUE98[F,?[*3&-P.I-P_85\)Q_E?M\$L7
M!>]3>O\ A>_W.S^\\K-J/-3]HMU^1^KU>+_M4?M>:;\"=.DTW36AU'Q5.G[N
MWSNCL@1P\V#[Y"=3[#DX?[7W[:-M\(8+CP[X<DCNO%,B8EF #Q:8#W/9I<=%
MZ#J>P/PYJ&JW.N:C<7EY<375W=.99II6+/*Y.2Q)ZDFOQR,>K/FFS2\1^+-2
M\<>(;K5-6O)K[4+QS)+-(<EB?3L .@ X X%5X?O57ME+L !DG@ =Z^H?V9?V
M$;CQ ;?7/&T,MGIYQ)!I>2DUP.QE(Y1?]D88_P"SWMM(D\W^ /[,VO\ QUOU
M>W0Z?HT;8GU&9#Y8]50?QM[#@=R*^WOA%\$M ^"F@_8M%M=LD@'VB[EPUQ<G
MU9L=/11@#TZUTVEZ7;:)IT-G9V\-K:VZ".*&) B1J.@ ' %6*RE*Y=@HHHJ1
MA1110 5\6?\ !;'_ (*-G]A?]G/^R?#=XD?Q&\=))9Z048&32X ,37I&>"FX
M+'GK(P."$85]B>*?$^G^"/#&I:UJUW#8:5I%K+>WMU*<1VT,:%Y)&/95523[
M"OY@?^"@_P"V)JG[<W[5/B3Q[?&XAT^ZE^R:+92-G^S[",D0Q^@8C+MC@O(Y
M[U]AP;D:Q^,]I57[NGJ_-]%^K\E;J>AEV%]K4O+9'B]Q<27EQ)--(\LLK%W=
MVW,['DDGN3ZTRBBOW0^H"OW>_P"#?S_@F]'^SG\%H_BSXKT\+XX\>6JOIT<T
M?[S1]+;#( #]V2?Y9&/4)Y:\'>#^8_\ P1[_ &)_^&W?VT-#TC4K/[1X/\,X
MUSQ#O7,<MO$PV6Y['SI"B$==AD(^[7]*$<:PQJJJJJHPJ@8 'H*_,^/\\<(K
M+J+UEK+TZ+Y[ORMW/%S;%67L8_,=1117Y.>"%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?A7_P '0&FRQ?MR^"[QMODS^!;:%3GG<FH7
MY;CZ2+7[J5^(O_!T=I<D7[4?PWO2R>5<>%G@4 _,&2[E8Y]OWBX^AK[+@25L
MVBNZE^1Z.5_[POF?F#1117[D?3GU5_P1&LY;[_@J5\)$A1I&6]O)"!V5=/N6
M8_@H)_"OZ3J_G*_X((64MW_P59^&,D:%DM4U:24_W%.DWB9_[Z91^-?T:U^,
M^(DO^%&"_N+_ -*D?.YQ_&7I^K"BBBO@3R0HHHH *_$__@Z4LHH_VBOA?<JF
M)IO#EQ&[>JK<DJ/P+M^=?MA7XT_\'4<:CXA_!IMJ[FT[5 6QR0);; _4_G7U
MO \K9Q37E+_TEGH99_O"^?Y'Y.T445^[GU![[_P2QL)M2_X*,_!>.%=[KXKL
MI2,@?*D@=CSZ*I/X5_3W7\S_ /P1STN35_\ @IK\'X8V1676C.2QXVQP2R-^
M.%./?%?TP5^/>(TO]MI1_N?JSY[./XD?0****_/#R HHHH **** "BBB@#\N
M?^#HOX0PZU^SS\./'20J;OP_K\NC2.J_-Y-W TOS'^Z'M% ST,AQC)S^)M?T
M*?\ !Q)HBZK_ ,$RO$%PVS.F:UIERNY<G)G$7!['$IY],CO7\]=?N' 59SRI
M1?V927Y/]3Z;*I7H6[-A1117VAZ1_5;^QAXPE^(/['OPIUZX8R7&L^#])O9F
M+;CYDEE$[9/KN)S[UZ77A?\ P3&MY+7_ ()X?!59(WC8^#M-<!EVDJUNC*?H
M000>X(KW2OYEQT5'$U(K92?YL^+JJTVO-A1117*9A1110!%?6,.IV<EO<PQ7
M%O,I22*5 Z2*>H(/!!]#7RU^T;^PFT8N-9\#QLZ\O-I+-EAZF%CU_P!P\]<$
M\+7U5134F@/ROU"UDL;B2&:.2&:)BCHZE61@<$$'D$>E.\,^+-2\$>(K;5-)
MO)K&_LWWQ31-@J?0^H/0@\$<'BOO7]HG]DS1?CE:R7D/EZ5XB5?DO$7Y9\=%
ME4?>';=]X>XXKX:^)WPPUOX2^*)-*URRDM+E.4;K'.O9T;HRGVZ=#@Y%:QDF
M1L?:W[+G[7>G?'*TCTO4O)T[Q3"F6@!Q'>@#EXO?N4ZCJ,@$CVBOR=@OY]+O
MHKFVFDM[BW<212QL5>-@<A@1R"#SD5]K?LC_ +;%O\3!;^'/%4T-KXBP$MKM
ML1Q:EV"^BR^W1NV#Q4RCU0TSZ,HHJKK>M6GAO1KS4;^XBM+&PA>YN9Y6VI#&
MBEF=CV 4$D^@K/?1%'Y;_P#!S5^U]_PB?PO\,?!G2;K;>^*)%US7%1_F6RA<
MBWC89^[).K/R.ML*_%FO8/V]_P!J6Z_;+_:U\:?$&<R+9ZQ?&/3(7SFVL8@(
M[=,=F\M5+8X+LQ[UE_L<?LXZA^UO^T[X+^'>G>8K^)M2C@N9D7<;6U7,EQ-C
M_IG"LCX[[<=Z_H3(L##*\LC"II9.4GYVN_NV^1];A:2H4$I>K/LKX;_\$C&\
M7?\ !$_7OBI_9I;XA7%Y_P );IOR'SO[%M@\3P=.!)&9KGY?O[(!7YTU_7)X
M<\%:5X3\%6'AW3[&WM]#TRRCTVVLPF8H[>.,1K%@\;0@"X/:OYD?^"E7[)LW
M[%G[9?C+P.L+QZ-%=&_T-SDB73Y\O!@G[Q0$Q,?[\35X/!_$<L?7KT:SU;YH
M^4=K?+3[V<N7XQU92C+U7H>$T445]\>J?TQ?\$C?VM?^&QOV%?!_B*[NA<^(
MM'B_L#726W.;RV55,CG^]+$8IC[S5]+5^%G_  ;7_M:_\*J_:CUCX7ZE=>7H
M_P 2+7S;%7;Y(]2ME9U SP/,A\U3W9DB'/%?NG7\^\497]1S&=.*]V7O1]'_
M ).Z^1\GCJ/LJSBMMT%%%%?.G&%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7XN_\'3>ER1?&7X2WI9/*N-%OH% /S!DGC8Y]OWB
MX^AK]HJ_&O\ X.H_^1_^#/\ V#]5_P#1EK7UG!#_ .%BEZ2_])9Z&6?[POG^
M1^3=%%%?O!]0?=W_  ;F_P#*2S2_^Q?U+_T!:_H*K^?7_@W-_P"4EFE_]B_J
M7_H"U_057XGX@?\ (T7^!?FSYK-OX_R04445\.>8%%%% !1110 4444 ?GK_
M ,'+UY';?\$\M,21U5KCQE81Q@_QM]FO&P/^ JQ_"OP1K]J/^#I;XC1Z?\#?
MA9X1\T>;JVNW6KF,'M:V_E!B/^WL@9]\=Z_%>OW+@.FXY3%O[3D_QM^A]/E<
M;4$_-A1117V1Z)_2%_P0JTV72O\ @E1\)XIMNYHM3F&#GY9-5O'7_P =85];
M5XW_ ,$\_AK)\(?V%_A+X=GC:*ZL/"M@UU&1S'/)"LLJ_A([#\.U>R5_-6:U
M55QM:HMI3D_O;9\97ES5)27=_F%%%%<!D%%%% !116=XO\6:?X"\):IKFK74
M=EI.BVDM_>W#_=@@B0O(Y]E52?PIQ3;L@/RD_P"#G+]K_P#L_0/"/P3TFY'G
M:@R^(]?"-RL2EH[2$XX^9Q+(5/(\J$]#7XYUZ;^V5^TCJ'[77[3_ (T^(FHA
MXW\2ZB\UM"QR;6U4".WASWV0I&N>Y4GO4W[$_P"S1??M?_M3>"_AY8B15\0:
MBB7LR#FULTS)<R_585<C/5@!WK^A<EP,,KRV,*FG*N:3\]W]VWHCZ[#4U0HI
M/U9^T/\ P;K?LB_\*(_8UD\=:E:^5X@^*5P+]2P^>+38MR6J_P# R99<CJLJ
M9'RU^@E4?#'AJP\%^&M/T?2K6*QTO2;:.SL[:(8CMX8U"(BCT50 /85>K\'S
M3'3QN*GBI[R=_1=%\E9'RU:JZE1S?4_%+_@YG_9!_P"$,^+_ (9^,NE6BII_
MC")=&UMT'2_@3]Q(WO);KL&.UKZGG\M*_J0_X*$?LJV_[9_[(7C3P"\<+:EJ
M5D;C2))#M%O?P_O+=MW\(,BA6/\ <=AT)K^7?5=+N-#U.XLKR&2VN[.5H)X9
M%VO$ZDJRD=B"""/:OV#@7-/K. ]A-^]3T_[=Z?JOD?0Y77YZ7*]X_ET*]>E?
MLC_M':U^RE\?M"\::%?7&GW%B[V]Q)%]YK:9#%,,=SL<E?1E4CD"O-:*^QKT
M85J<J5174DT_1GH2BI1<7LS]@(-3_MI?MGGFZ^UCSO.+[S-NYW9[YSG/?-;7
MA#PIJ7C?7;?2])LY]0U"[8)%#"N68_R '4DX ')P*\C_ ."2>EZ_^U_\-+7P
MWI<?G:CX49;&_N96/E6MN<F"20]@5!0#DL8FP.#C]>/V?_V;M _9\\/?9].C
M^U:E<*/M>HRJ/.G/H/[J#LH_')YK^<LRPLL'B9X:>\7;_)_-:GQ=6BZ<W!]#
MB/V7OV*--^$$=OK.OK!JOB7 =!C=;Z>?]@'[SC^^>G;'4^\T45YK=R0HHHH
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MG]IM_+HODK(^,K5'4J.;ZA1117"9!1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_&O\ X.H_^1_^#/\
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M?L#1117\]GR04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOKZZF.%AB12S'U)XP .22  20*V+R]ATZSFN+B6.WM[=#)++(P5(U R68G@
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M .#J/_D?_@S_ -@_5?\ T9:U^RE?C7_P=1_\C_\ !G_L'ZK_ .C+6OK."?\
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M^[5?-?\ P26_9&_X8R_8;\(^&KNU%KXBU:/^W=>!7#_;;A58HW'WHHQ%"?\
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MZ,IQU^H.""!^NE<'^T!^SQH'[17@UM+UB+RKB+Y[._B4>?9OZJ>ZGNIX(]"
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MOGQ#\220W'Q"\?\ AGPM:MAFMM(@EU2ZQW5BWE1JW7E6D XZ]*\%_P""./\
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M\H_VBOV<?$?[+?C];>Z:9[,R>=I>K0 HDX!RI!'W)%P,KG((R,C!/VI^PO\
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M (-S?^4EFE_]B_J7_H"U_057XGX@?\C1?X%^;/FLV_C_ "04445\.>8%%%%
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MD_8 _8A'CF6U\<>,+,-HD9\S2]/F7_C_ &!XFD!_Y9#'"G[YY/RCYL#]A_\
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MB"-<DXZHXQ^.<?C7]-5?R[_\$S]1BTO_ (*%_!229BJ-XTTN$$#/S/=1HO\
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M^,LR^J99/E?O3]U?/?\ "YZ>8UO9T7;=Z'W51117X*?*A1110 4444 %%%%
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M^%L9]\5_5-7Y'XD1_P!IHR_NO\SY_./CB_(****_-SQPHHHH **** "BBB@
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M$E6YVLV"!\LU^WX3&4<525;#R4HOJOZW\CZ:G4C./-!W1]F_\$E?^"M6N_\
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ML8=SM50=M?.?Q'^)7B#XO^-=0\1^*-8U'7]=U20RW5]?3M--,WNS=@,  <
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MYE;=LRT?4[3^5?U65^8^(TH3EAY0:>DMO^W3Q<X:;@UY_H%%%%?F9XH4444
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M0HHHK\S/%"BBB@ HHHH **** "BBB@ HHHH **** "OBO_@OC^S/_P -"_\
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MK X(/J*^P/V2O^"XWQ[_ &4[>UTW_A((O'7ANWPBZ9XE5KLQ(.,1W 83)@<
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M9M]OU1\/T5ZY:_L!?'B^MHYH?@G\7)H9 &1T\'Z@RN#W!$.#3_\ AWQ\?/\
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M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ*KZ1#<6VDVL=Y,MS=1Q(LTRIM$K@ ,P Z9.3CMFK%2,**** "BBB@ HHHH
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MJM*A,0HHHK,H**** "OR9_:S_P"3F?'7_8:N?_1AK]9J_)G]K/\ Y.9\=?\
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MRG:AP0017HOPA^/OA3X[P:A-X5U)M4@TUTCN)/LLT"JS D >8JD\#M[5P_\
MP[O^#O\ T)__ )5;W_X]7<_"'X!^$_@/:7UOX4TMM+AU%TDN$^U33AV4$ _O
M';'!/3&>*- U.QHHHJ1A7P1_P5&^ VH:-\2(_'EI;R3:3K$,4%]*BY^RW$:B
M-=_HKH$ /JI'<9^]ZKZII5KKFG36=[;6]Y:7*&.:">,21RJ>JLIR"#Z&JC*S
M ^._^"=O[8?ASPY\.8_!/BK5+719M+ED?3[J\D$=O-"[%RAD;A65V;[Q ((
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M]E&>D,.H90?BZLWZUZ#\'_V2? /P-OA>:!H,,>I %1>W,C7%PH/!VLY.S/\
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M@3X?:)\,?#L>D^'],M-)T^(EA#;IM!8]6)ZLQP,DDDX%;%2,^4?VUOV]M>^
M_P 3X_"_AG3]+DDM;>.XO+F^C>3<SY(1%5EP N"6R<DXXQD^V?LO?' _M"_!
MK3?$LEFMA=3L\%S"A)C65&VL4)YVG@C/(SC)QDY_QV_8[\$_M#ZU:ZEKUI=Q
MZE:QB'[39S^3)-&#D*_!# 9.#C(SUQ7<_#_P!I/PN\'V.@Z'9I8Z7IZ;(8E)
M.,DDDD\EB222>2235:6%J;-%%%2,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "JFOZ.GB'0KW3Y))H8[Z"2W:2%@LD8=2I*D@@,,
MY!(/-6Z* .9^#_PFTCX(_#[3_#>BQLEG8KS(^#)<2'EI'( RS'D]N@&  *Z:
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
